Adaptimmune Therapeutics Résultats passés
Passé contrôle des critères 0/6
Adaptimmune Therapeutics has been growing earnings at an average annual rate of 2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 56.5% per year.
Informations clés
2.0%
Taux de croissance des bénéfices
14.9%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | 56.5% |
Rendement des fonds propres | -75.3% |
Marge nette | -51.3% |
Prochaine mise à jour des résultats | 13 Nov 2024 |
Mises à jour récentes des performances passées
Recent updates
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Ventilation des recettes et des dépenses
Comment Adaptimmune Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 141 | -72 | 79 | 0 |
31 Mar 24 | 18 | -163 | 77 | 0 |
31 Dec 23 | 60 | -114 | 72 | 0 |
30 Sep 23 | 71 | -95 | 61 | -67 |
30 Jun 23 | 71 | -91 | 61 | 0 |
31 Mar 23 | 71 | -114 | 59 | 0 |
31 Dec 22 | 27 | -165 | 61 | 0 |
30 Sep 22 | 18 | -175 | 63 | 105 |
30 Jun 22 | 12 | -176 | 61 | 0 |
31 Mar 22 | 9 | -171 | 60 | 0 |
31 Dec 21 | 6 | -158 | 57 | 0 |
30 Sep 21 | 6 | -156 | 56 | 0 |
30 Jun 21 | 6 | -149 | 54 | 0 |
31 Mar 21 | 4 | -140 | 50 | 0 |
31 Dec 20 | 4 | -130 | 46 | 0 |
30 Sep 20 | 3 | -123 | 43 | 0 |
30 Jun 20 | 2 | -127 | 41 | 0 |
31 Mar 20 | 2 | -138 | 41 | 0 |
31 Dec 19 | 1 | -137 | 43 | 0 |
30 Sep 19 | 2 | -144 | 43 | 0 |
30 Jun 19 | 42 | -99 | 43 | 0 |
31 Mar 19 | 51 | -102 | 44 | 0 |
31 Dec 18 | 60 | -96 | 44 | 0 |
30 Sep 18 | 62 | -87 | 42 | 0 |
30 Jun 18 | 49 | -93 | 39 | 0 |
31 Mar 18 | 43 | -69 | 36 | -19 |
31 Dec 17 | 38 | -70 | 31 | 0 |
30 Sep 17 | 42 | -58 | 29 | 17 |
30 Jun 17 | 17 | -76 | 26 | 32 |
31 Mar 17 | 14 | -78 | 24 | 68 |
31 Dec 16 | 14 | -72 | 23 | 0 |
30 Sep 16 | 10 | -73 | 23 | 63 |
30 Jun 16 | 12 | -61 | 21 | 57 |
31 Mar 16 | 15 | -55 | 21 | 48 |
31 Dec 15 | 14 | -48 | 18 | 40 |
30 Sep 15 | 13 | -19 | 14 | 29 |
30 Jun 15 | 10 | -37 | 10 | 24 |
31 Mar 15 | 7 | -16 | 8 | 19 |
31 Dec 14 | 4 | -12 | 5 | 16 |
30 Sep 14 | 2 | -13 | 4 | 14 |
30 Jun 14 | 1 | -12 | 3 | 10 |
Des revenus de qualité: ADAP is currently unprofitable.
Augmentation de la marge bénéficiaire: ADAP is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ADAP is unprofitable, but has reduced losses over the past 5 years at a rate of 2% per year.
Accélération de la croissance: Unable to compare ADAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: ADAP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement des fonds propres
ROE élevé: ADAP has a negative Return on Equity (-75.31%), as it is currently unprofitable.